{"entity":{"id":"nct02227251","kind":"trial","name":"Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","aka":[],"tldr":"A phase 2 trial of Selinexor in diffuse large b-cell lymphoma, run by Karyopharm Therapeutics Inc, active and no longer recruiting.","summary":"Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) is a phase 2 interventional study registered as NCT02227251 by Karyopharm Therapeutics Inc, with 244 participants planned, started 2014-11 and due to reach its primary completion in 2026-12. Interventions recorded: Selinexor, Selinexor, Selinexor. Conditions listed: Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT02227251","url":"https://clinicaltrials.gov/study/NCT02227251"}],"tags":["ctgov-ingest"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":["selinexor"],"companies":["karyopharm"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT02227251","phase":"2","setting":"A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","sponsor":"Karyopharm Therapeutics Inc","enrolled":244,"outcomes":[]},"route":"/trials/nct02227251/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"drug":[{"id":"selinexor","kind":"drug","name":"Selinexor","route":"/drugs/selinexor/"}],"company":[{"id":"karyopharm","kind":"company","name":"Karyopharm Therapeutics","route":"/companies/karyopharm/"}]}}